汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002412 汉森制药

已收盘 01-13 15:00:00

{"stockData":{"symbol":"002412","market":"SZ","secType":"STK","nameCN":"汉森制药","latestPrice":6.83,"timestamp":1768287795000,"preClose":6.81,"halted":0,"volume":13693999,"delay":0,"changeRate":0.0029,"floatShares":498000000,"shares":503000000,"eps":0.3419,"marketStatus":"已收盘","change":0.02,"latestTime":"01-13 15:00:00","open":6.83,"high":6.94,"low":6.76,"amount":94132300,"amplitude":0.0264,"askPrice":6.84,"askSize":736,"bidPrice":6.83,"bidSize":1167,"shortable":0,"etf":0,"ttmEps":0.3419,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":6.81,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":7.49,"lowLimit":6.13,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":503200000,"isCdr":false,"pbRate":1.52,"roa":"--","peRate":19.976601,"roe":"3.69%","epsLYR":0.4377,"committee":0.140266,"marketValue":3437000000,"turnoverRate":0.0275,"status":0,"floatMarketCap":3400000000},"requestUrl":"/m/hq/s/002412","defaultTab":"news","newsList":[{"id":"2602539469","title":"股市必读：汉森制药（002412）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602539469?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:58","pubTimestamp":1767895090,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，汉森制药报收于6.69元，上涨2.45%，换手率2.01%，成交量10.03万手，成交额6662.22万元。董秘最新回复投资者： 同属湖南的中成药公司方盛制药2024年又特别分红，每年中期也分红，而贵公司汉森制药几年不见分红一次，股价又不涨，如何体现贵公司所说的已持续稳定的业绩汇报投资者，难道只是口头说说？当日关注点来自：1月8日主力资金净流入668.21万元，显示主力对汉森制药短期走势持积极态度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0028","BK0039"],"gpt_icon":0},{"id":"2593889174","title":"汉森制药：截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2593889174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593889174?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:54","pubTimestamp":1766393661,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问公司到十二月二十日的股东人数，谢谢汉森制药回复：尊敬的投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年11月28日，公司含信用账户合并股东名册的股东总数为：24145人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200019844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","002412","BK0239"],"gpt_icon":0},{"id":"2592164248","title":"汉森制药：坚守中成药主业做大做强","url":"https://stock-news.laohu8.com/highlight/detail?id=2592164248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592164248?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148720,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司有考虑加大中药研究和发扬光大中药吗？谢谢汉森制药回复：尊敬的投资者您好，公司“一体两翼”发展战略中，明确了坚守中成药主业，立足中成药主业进行产业延伸和融合，通过内生增长和外延发展“双轮驱动”，做大做强中成药主业。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900036453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0239","002412","BK0028"],"gpt_icon":0},{"id":"2591616226","title":"汉森制药：截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616226?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:09","pubTimestamp":1765786149,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月10日股东人数是多少？汉森制药回复：尊敬的投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年11月28日，公司含信用账户合并股东名册的股东总数为：24145人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500015157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0039","BK0028","BK0239"],"gpt_icon":0},{"id":"2590375842","title":"汉森制药：该事项有助于公司实现整合资源、提升产能利用及扩大普药销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590375842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590375842?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:51","pubTimestamp":1765327871,"startTime":"0","endTime":"0","summary":"投资者提问：据报道91届药交会上，汉森制药携省级联盟集采产品四磨汤口服液、银杏叶胶囊，基药产品缩泉胶囊、感冒清热颗粒，特色产品天麻醒脑胶囊、百贝益肺胶囊、参七心疏胶囊参展，重磅推出汉森普药贴牌直招，请问贵公司推出汉森普药贴牌直招是对公司来说是利好吗，如何看待后续业务合规性，谢谢汉森制药回复：尊敬的投资者您好，该事项有助于公司实现整合资源、提升产能利用及扩大普药销售。公司将坚持合规生产与经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000005113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0039","BK0028"],"gpt_icon":0},{"id":"2588803353","title":"汉森制药：截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803353?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:12","pubTimestamp":1764663144,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日的股东人数是多少？谢谢汉森制药回复：投资者您好，截至2025年11月28日，公司含信用账户合并股东名册的股东总数为：24145人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200019544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","002412","BK0239"],"gpt_icon":0},{"id":"2586385411","title":"汉森制药：苁蓉颗粒处于工艺中试放大阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2586385411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586385411?lang=zh_cn&edition=full","pubTime":"2025-11-25 08:33","pubTimestamp":1764030785,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司在研发方面有取得进展成果吗？谢谢汉森制药回复：尊敬的投资者您好，公司在研发方面，中药新药苁蓉颗粒正处于工艺中试放大研究阶段。后续如有重大进展情况，将严格遵守信息披露相关规定。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500004320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0028","BK0039"],"gpt_icon":0},{"id":"2585599468","title":"汉森制药(002412)10月31日股东户数2.39万户，较上期增加2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585599468","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585599468?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:47","pubTimestamp":1763977633,"startTime":"0","endTime":"0","summary":"证券之星消息，近日汉森制药披露，截至2025年10月31日公司股东户数为2.39万户，较9月30日增加643.0户，增幅为2.76%。在中药行业个股中，汉森制药股东户数低于行业平均水平，截至10月31日，中药行业平均股东户数为5.34万户。从股价来看，2025年9月30日至2025年10月31日，汉森制药区间涨幅为0.16%，在此期间股东户数增加643.0户，增幅为2.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400022593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0239","BK0039","BK0028"],"gpt_icon":0},{"id":"2584916844","title":"汉森制药：目前公司暂无海外客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2584916844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584916844?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:15","pubTimestamp":1763540127,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)11月19日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司通过多年经营，树立了良好的口碑和较好的用户基础，请问有无海外的客户基础？如果有，是否涉及欧盟国家？汉森制药回复：尊敬的投资者您好，目前公司暂无海外客户。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900023030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002412","BK0239","BK0039"],"gpt_icon":0},{"id":"2583549984","title":"汉森制药：有感冒清热颗粒等感冒药","url":"https://stock-news.laohu8.com/highlight/detail?id=2583549984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583549984?lang=zh_cn&edition=full","pubTime":"2025-11-14 08:45","pubTimestamp":1763081113,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问：今冬明春流感暴发，汉森制药有感冒药吗？谢谢汉森制药回复：尊敬的投资者您好，公司（含全资子公司）有治疗感冒的相关产品，如感冒清热颗粒、百贝益肺胶囊、复方氨酚烷胺片、藿香正气水等。具体产品信息您可查阅公司官网。药品使用谨遵医嘱！感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400006186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","BK0028","002412"],"gpt_icon":0},{"id":"2583059184","title":"汉森制药（002412）披露2025年第一次临时股东大会决议公告，11月13日股价上涨1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583059184","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583059184?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:50","pubTimestamp":1763045429,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，汉森制药报收于6.96元，较前一交易日上涨1.46%，最新总市值为35.02亿元。近日，汉森制药发布2025年第一次临时股东大会决议公告。公告显示，公司于2025年11月13日召开2025年第一次临时股东大会，会议由董事会召集，董事长刘正清主持。出席股东及授权代表共102人，代表有表决权股份221,226,929股，占公司总股本的43.9640%。湖南启元律师事务所对本次会议出具法律意见书，认为会议召集、召开程序及表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002412","BK0039","BK0028"],"gpt_icon":0},{"id":"2583599661","title":"汉森制药：选举职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2583599661","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583599661?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:08","pubTimestamp":1763042880,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月13日晚间，汉森制药发布公告称，公司于2025年11月13日在公司一楼大会议室召开第四届第二次职工代表大会，经与会职工代表认真审议，同意选举胡琼女士为公司第六届董事会职工代表董事。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2292989.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2292989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0039","002412","BK0239"],"gpt_icon":0},{"id":"2581637467","title":"股市必读：汉森制药(002412)股东户数2.39万户，较上期增加2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581637467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581637467?lang=zh_cn&edition=full","pubTime":"2025-11-05 03:44","pubTimestamp":1762285454,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，汉森制药报收于6.52元，上涨0.77%，换手率1.75%，成交量8.72万手，成交额5655.3万元。交易信息汇总资金流向11月4日主力资金净流出246.17万元，占总成交额4.35%；游资资金净流出17.37万元，占总成交额0.31%；散户资金净流入263.53万元，占总成交额4.66%。股本股东变化股东户数变动截至2025年10月31日，汉森制药股东户数为2.39万户，较9月30日增加643户，增幅2.76%；户均持股数量由上期的2.16万股下降至2.1万股，户均持股市值为13.39万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500002908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002412","BK0239","BK0039"],"gpt_icon":0},{"id":"2579144213","title":"汉森制药：公司始终坚守中成药主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2579144213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579144213?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:51","pubTimestamp":1761828693,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药10月29日在投资者关系平台上答复投资者关心的问题。汉森制药业绩下滑，主因参股公司投资收益大减拖累净利润，核心业务扣非净利润同比降超8成；叠加销售费用占比超37%、三费合计占比44.62%，费用转化效率低；且长期依赖四磨汤口服液，单一产品抗风险能力弱。公司将致力于长远发展目标，为股东创造更大价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0239","BK0039"],"gpt_icon":0},{"id":"2579391522","title":"汉森制药（002412）2025年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2579391522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579391522?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:29","pubTimestamp":1761690568,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期汉森制药发布2025年三季报。根据财报显示，汉森制药增收不增利。截至本报告期末，公司营业总收入7.41亿元，同比上升6.75%，归母净利润8252.52万元，同比下降36.88%。按单季度数据看，第三季度营业总收入2.32亿元，同比上升8.62%，第三季度归母净利润1398.68万元，同比下降53.78%。如有转让股权相关重大事项，公司将会及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900009397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002412","BK0239","BK0039"],"gpt_icon":0},{"id":"2578562474","title":"图解汉森制药三季报：第三季度单季净利润同比下降53.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578562474","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578562474?lang=zh_cn&edition=full","pubTime":"2025-10-28 02:13","pubTimestamp":1761588788,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药2025年三季报显示，公司主营收入7.41亿元，同比上升6.75%；归母净利润8252.52万元，同比下降36.88%；扣非净利润7713.8万元，同比下降37.24%；其中2025年第三季度，公司单季度主营收入2.32亿元，同比上升8.62%；单季度归母净利润1398.68万元，同比下降53.78%；单季度扣非净利润1236.85万元，同比下降55.92%；负债率11.77%，投资收益-5563.48万元，财务费用48.72万元，毛利率77.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800001905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412"],"gpt_icon":0},{"id":"2577583229","title":"汉森制药（002412）披露控股股东部分股份解除质押，10月23日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577583229","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577583229?lang=zh_cn&edition=full","pubTime":"2025-10-23 22:26","pubTimestamp":1761229574,"startTime":"0","endTime":"0","summary":"本次解除质押股份数量为24,500,000股，占其所持股份比例11.56%，占公司总股本比例4.87%，质押起始日为2021年6月21日，解除日期为2025年10月22日，质权人为交通银行股份有限公司益阳分行。截至公告披露日，海南汉森持股数量为212,006,189股，持股比例42.13%，累计质押股份数量10,000,000股，占其所持股份比例4.72%，占公司总股本比例1.99%。已质押股份和未质押股份中无限售或冻结情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300037860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0239","BK0039"],"gpt_icon":0},{"id":"2574972941","title":"股市必读：汉森制药（002412）9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2574972941","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574972941?lang=zh_cn&edition=full","pubTime":"2025-10-09 04:10","pubTimestamp":1759954225,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，汉森制药报收于6.36元，下跌0.62%，换手率1.07%，成交量5.32万手，成交额3390.1万元。董秘最新回复投资者： 你好，请问作为儿童药的四磨汤口服液是否有望入选新版的国家基药目录，还有天麻醒脑胶囊，谢谢董秘： 尊敬的投资者您好，目前未见调整新版国家基药目录的官方信息。当日关注点来自交易信息汇总：9月30日主力资金净流出330.36万元，占总成交额9.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900001172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","002412","BK0028"],"gpt_icon":0},{"id":"2570026659","title":"汉森制药：中药新药苁蓉颗粒处于中试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2570026659","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570026659?lang=zh_cn&edition=full","pubTime":"2025-09-26 08:51","pubTimestamp":1758847875,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司今年的研发计划里面，创新药占比多少？谢谢汉森制药回复：尊敬的投资者您好，公司在产品研发方面，中药新药苁蓉颗粒正处于工艺中试放大研究阶段。具体情况请参考公司2024年度报告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600005457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","002412","BK0239"],"gpt_icon":0},{"id":"2569754943","title":"汉森制药：截至2025年8月29日股东总数为23580人","url":"https://stock-news.laohu8.com/highlight/detail?id=2569754943","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569754943?lang=zh_cn&edition=full","pubTime":"2025-09-23 09:01","pubTimestamp":1758589283,"startTime":"0","endTime":"0","summary":"证券之星消息，汉森制药(002412)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司9月20日的股东人数是多少？谢谢汉森制药回复：投资者您好，公司可在互动易平台回复非定期报告时点的月末股东人数，截至2025年8月29日，公司含信用账户合并股东名册的股东总数为：23580人。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300006001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","BK0239","002412"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768329559386,"stockEarnings":[{"period":"1week","weight":0.0364},{"period":"1month","weight":0.0427},{"period":"3month","weight":0.0492},{"period":"6month","weight":0.0149},{"period":"1year","weight":0.2046},{"period":"ytd","weight":0.0655}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南汉森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"24145人(较上一季度增加0.85%)","perCapita":"20618股","listingDate":"2010-05-25","address":"湖南省益阳市赫山区银城大道2688号","registeredCapital":"50320万元","survey":"　　湖南汉森制药股份有限公司的主营业务是生产中药制剂、化学药。公司的主要产品是四磨汤口服液、缩泉胶囊、银杏叶胶囊、天麻醒脑胶囊、愈伤灵胶囊、百贝益肺胶囊、利胆止痛胶囊、胃肠灵胶囊、藿香正气水、玉竹膏、通关藤胶囊、参七心疏胶囊、感冒清热颗粒、人工牛黄甲硝唑胶囊、氢溴酸右美沙芬颗粒、复方氨酚烷胺片、卡托普利片、甲硝唑片、碳酸氢钠片、碘海醇注射液、碘帕醇注射液、泛影葡胺注射液。","listedPrice":35.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汉森制药,002412,汉森制药股票,汉森制药股票老虎,汉森制药股票老虎国际,汉森制药行情,汉森制药股票行情,汉森制药股价,汉森制药股市,汉森制药股票价格,汉森制药股票交易,汉森制药股票购买,汉森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}